Samira Curdt

Roche (Switzerland) — Switzerland

Medicine · Health Sciences

2h-index20citations16works0.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(15), HER2/EGFR in Cancer Research(10), Radiopharmaceutical Chemistry and Applications(9), Chronic Lymphocytic Leukemia Research(3), Monoclonal and Polyclonal Antibodies Research(2)

Publications16 total

Supplementary Figure 4 from Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
2025Open Access
Supplementary Figure 2 from Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
2025Open Access
Table 1 from Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
2025Open Access
Table 3 from Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
2025Open Access
Table 4 from Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
2025Open Access
Supplementary Figure 1A and 1B from Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
2025Open Access
Supplementary Figure 3 from Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
2025Open Access
Table S1. from Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
2025Open Access
Table 2 from Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
2025Open Access
Figure 1 from Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
2025Open Access
Figure 2 from Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
2025Open Access
Data from Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
2025Open Access
Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors
Cancer Research Communications·2025· 10 citedOpen Access
Abstract CT176: Pharmacokinetic/pharmacodynamic (PK/PD) relationships of the novel Treg depleter RG6292 in Phase Ia and Ib studies in patients with solid tumors
Cancer Research·2023· 2 cited
Abstract CT110: Safety and anti-tumor activity of a novel Treg depleter RG6292, as a single agent and in combination with atezolizumab in patients with solid tumors
Cancer Research·2023· 2 cited
Phase 1 Study of CD19 Targeted CD28 Costimulatory Agonist in Combination with Glofitamab to Enhance T Cell Effector Function in Relapsed/Refractory B Cell Lymphoma
Blood·2022· 6 cited

Frequent Co-authors

Valentina Gambardella(15), Michael Ong(15), Jean‐Pascal Machiels(15), Miguel F. Sanmamed(15), Anna Spreafico(15), Daniel J. Renouf(15), Rachel Galot(15), Emiliano Calvo(15), Tamara Tanos(15), Kevin Smart(15), Linxinyu Xu(15), Christophe Boetsch(15), Vaios Karanikas(15), Gabriel Schnetzler(15), Kristoffer Staal Rohrberg(15), Stephen J. Luen(14), Aung Naing(14), Eva Rossmann(14), Maria Amann(14), Yuying Xie(14)